A Phase I/II Study of Pazopanib (GW786034) and Cyclophosphamide in Patients With Platinum-resistant Recurrent, Pre-treated Ovarian Cancer.

Trial Profile

A Phase I/II Study of Pazopanib (GW786034) and Cyclophosphamide in Patients With Platinum-resistant Recurrent, Pre-treated Ovarian Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 May 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; Pazopanib (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PACOVAR
  • Most Recent Events

    • 18 May 2017 Results (n=16) of phase 1 assessing tolerability of pazopanib and cyclophosphamide published in the Gynecologic Oncology.
    • 09 Feb 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 21 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top